Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Dihon

- PMLiVE

Interview: Pierre Chancel, Sanofi Diabetes

The head of Sanofi Diabetes shares the company’s strategy to keep pace with the race against this ‘hidden disease’

- PMLiVE

Merck Serono signs diabetes partnership with BMS in China

Will co-promote Glucophage (metformin) formulations

- PMLiVE

Bayer’s Eylea data not suitable, says IQWiG

German HTA body unhappy with Lucentis comparison data and turns down Bayer-Regeneron wet AMD drug

China: Engagement strategies

As China grows apace, digital is increasingly being used to engage both customers and patients

- PMLiVE

Bayer sues Glenmark over its skin disorder generic

India-based firm files for US approval of its version of Finacea

- PMLiVE

ACC and Boehringer develop CME programme in China

Will focus on stroke prevention in atrial fibrillation

- PMLiVE

WuXi Pharmatech and OMT expand antibodies agreement

Enables Chinese CRO to increase its service offering

- PMLiVE

FDA knocks back Xarelto once again in ACS

Major setback for Bayer and Johnson & Johnson's oral anticoagulant

- PMLiVE

Bayer fails to overturn Nexavar compulsory licence in India

Natco Pharma allowed to sell cut-price version of cancer drug

- PMLiVE

Bayer pins hopes on five potential blockbusters

Riociguat, alpharadin, Stivarga, Eylea, and Xarelto expected to reach sales of €5.5bn by 2015

- PMLiVE

Second approval in US for Bayer-Onyx’ Stivarga

FDA clears drug to treat patients with gastrointestinal stromal tumours

- PMLiVE

FDA fast-tracks Bayer’s prostate cancer radiotherapy

Priority review for radium-223 dichloride, formerly called Alpharadin

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links